The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...

The order comes after Sony said it would take over distribution for the two syndicated game shows The post CBS Granted ...

2 Hilton Court: A 113,000-square foot office building last occupied by Daiichi Sankyo in 2016 was demolished last year to ...

Big Pharma often turns to NFL games to hawk their blockbuster treatments, but drug makers have typically been hesitant to ...

Daiichi Sankyo’s Q3 FY2024 results reflect strong performance in oncology, driven by ENHERTU’s market leadership and robust sales growth across regions. Despite regulatory delays for Datroway ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for ...

Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...

Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently ...

(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive Officer, succeeding Sunao Manabe, with effect from ...

TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...

This is Okuzawa and starting from April, I'll be taking this heavy responsibility of CEO of Daiichi Sankyo. The purpose is to make a contribution to the rich and healthy life for the people in the ...